Pharma Cos. Rip FTC's Bid To Bar Pay-For-Delay Deals
The Federal Trade Commission's bid to make so-called pay-for-delay settlements presumptively illegal undervalues patents and would wreak havoc on courts forced to relitigate patent cases amid antitrust disputes, several drugmakers told...To view the full article, register now.
Already a subscriber? Click here to view full article